Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q16518: Variant p.Thr101Ile

Retinoid isomerohydrolase
Gene: RPE65
Feedback?
Variant information Variant position: help 101 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Threonine (T) to Isoleucine (I) at position 101 (T101I, p.Thr101Ile). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and polar (T) to medium size and hydrophobic (I) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In LCA2; severely decreased retinol isomerase activity. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 101 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 533 The length of the canonical sequence.
Location on the sequence: help RRFIRTDAYVRAMTEKRIVI T EFGTCAFPDPCKNIFSRFFS The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         RRFIRTDAYVRAMTEKRIVITEFGTCAFPDPCKNIFSRFFS

                              RRFIRTDAYVRAMTEKRIVITEFGTCAFPDPCKNIFSRFFS

Mouse                         RRFIRTDAYVRAMTEKRIVITEFGTCAFPDPCKNIFSRFFS

Rat                           RRFIRTDAYVRAMTEKRIVITEFGTCAFPDPCKNIFSRFFS

Bovine                        RRFIRTDAYVRAMTEKRIVITEFGTCAFPDPCKNIFSRFFS

Chicken                       RRFVRTDAYVRAMTEKRIVITEFGTYAYPDPCKNIFSRFFS
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 2 – 533 Retinoid isomerohydrolase
Modified residue 101 – 101 Phosphothreonine
Modified residue 105 – 105 Phosphothreonine
Modified residue 113 – 113 N6-acetyllysine
Modified residue 117 – 117 Phosphoserine
Lipidation 112 – 112 S-palmitoyl cysteine; in membrane form
Mutagenesis 106 – 106 C -> A. No loss of enzymatic activity. No effect on palmitoylation. No loss of membrane association.
Mutagenesis 106 – 106 C -> Y. Does not affect isomerohydrolase activity.
Mutagenesis 112 – 112 C -> A. Loss of enzymatic activity. No palmitoylation. Loss of membrane association.



Literature citations
Leber congenital amaurosis - a model for efficient genetic testing of heterogeneous disorders: LXIV Edward Jackson Memorial Lecture.
Stone E.M.;
Am. J. Ophthalmol. 144:791-811(2007)
Cited for: VARIANTS LCA2 ILE-101; SER-118; PRO-162; ASN-318; 402-TRP--SER-533 DEL; PRO-408; ALA-443; 460-TRP--SER-533 DEL AND THR-533; Predicting the pathogenicity of RPE65 mutations.
Philp A.R.; Jin M.; Li S.; Schindler E.I.; Iannaccone A.; Lam B.L.; Weleber R.G.; Fishman G.A.; Jacobson S.G.; Mullins R.F.; Travis G.H.; Stone E.M.;
Hum. Mutat. 30:1183-1188(2009)
Cited for: CHARACTERIZATION OF VARIANTS LCA2 SER-40; GLN-44; GLN-91; TRP-91; ILE-101; ASP-239; ASN-318; PRO-408 AND VAL-434; CHARACTERIZATION OF VARIANT LYS-321; CHARACTERIZATION OF VARIANT RP20 THR-294;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.